Ibritumomab Tiuxetan Overview

Ibritumomab tiuxetan, also sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for some forms of B cell non-Hodgkin's lymphoma, a myeloproliferative disorder of the lymphatic system. The drug uses the monoclonal mouse IgG1 antibody ibritumomab in conjunction with the chelator tiuxetan, to which a radioactive isotope is added. The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells ,...